GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaLundensis AB (XSAT:PHAL) » Definitions » Cyclically Adjusted Price-to-FCF

PharmaLundensis AB (XSAT:PHAL) Cyclically Adjusted Price-to-FCF : (As of Jun. 11, 2024)


View and export this data going back to 2010. Start your Free Trial

What is PharmaLundensis AB Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


PharmaLundensis AB Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for PharmaLundensis AB's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaLundensis AB Cyclically Adjusted Price-to-FCF Chart

PharmaLundensis AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

PharmaLundensis AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PharmaLundensis AB's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, PharmaLundensis AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaLundensis AB's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaLundensis AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where PharmaLundensis AB's Cyclically Adjusted Price-to-FCF falls into.



PharmaLundensis AB Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

PharmaLundensis AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, PharmaLundensis AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.023/132.2054*132.2054
=-0.023

Current CPI (Mar. 2024) = 132.2054.

PharmaLundensis AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.076 100.432 -0.100
201409 -0.118 100.161 -0.156
201412 0.000 100.225 0.000
201503 -0.039 99.950 -0.052
201506 -0.071 99.995 -0.094
201509 -0.123 100.228 -0.162
201512 0.000 100.276 0.000
201603 -0.022 100.751 -0.029
201606 -0.105 101.019 -0.137
201609 -0.075 101.138 -0.098
201612 0.000 102.022 0.000
201703 -0.055 102.022 -0.071
201706 -0.131 102.752 -0.169
201709 -0.087 103.279 -0.111
201712 0.000 103.793 0.000
201803 -0.058 103.962 -0.074
201806 -0.050 104.875 -0.063
201809 -0.077 105.679 -0.096
201812 0.000 105.912 0.000
201903 -0.044 105.886 -0.055
201906 -0.080 106.742 -0.099
201909 -0.037 107.214 -0.046
201912 0.000 107.766 0.000
202003 -0.049 106.563 -0.061
202006 -0.067 107.498 -0.082
202009 0.011 107.635 0.014
202012 0.000 108.296 0.000
202103 -0.017 108.360 -0.021
202106 -0.034 108.928 -0.041
202109 -0.026 110.338 -0.031
202112 0.000 112.486 0.000
202203 -0.024 114.825 -0.028
202206 -0.006 118.384 -0.007
202209 -0.036 122.296 -0.039
202212 0.000 126.365 0.000
202303 -0.006 127.042 -0.006
202306 -0.032 129.407 -0.033
202309 -0.033 130.224 -0.034
202312 0.000 131.912 0.000
202403 -0.023 132.205 -0.023

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


PharmaLundensis AB  (XSAT:PHAL) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


PharmaLundensis AB Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of PharmaLundensis AB's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaLundensis AB (XSAT:PHAL) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Medicon Village, Scheelevagen 2, Lund, SWE, 22381
PharmaLundensis AB is a Sweden based drug manufacturing company, The company focuses on the development and marketing of pharmaceuticals. It is engaged in developing drugs for the lung diseases, such as chronic obstructive pulmonary disease and asthma, as well as drugs for mercury toxicology.

PharmaLundensis AB (XSAT:PHAL) Headlines

No Headlines